1. Scrip
  2. >>R&D

J&J Exec On COVID-19 Vaccine: Moving At High Speed But No Safety Compromises

'Different Way Of Working'

 
• By Anju Ghangurde

J&J executive emphasizes that fast-tracked development of COVID-19 vaccines does not come with any corners cut around safety. Indian partner Biological E also outlines the complexities in manufacturing and believes that the candidates from J&J, AstraZeneca and others will be more suitable in profile and price terms to contain the pandemic globally.

Vaccine and syringe injection. It use for prevention,immunization and treatment from corona virus infection(novel coronavirus disease 2019,COVID-19,nCoV 2019 from Wuhan). Medicine infectious concept.
COVID-19 Vaccines Fast-Tracked But No Corners Cut • Source: Shutterstock

As COVID-19 vaccines for adults roll out in some parts of the world, the pharma industry continues to underscore that the fast-tracked arrival of these immunization shots does not mean any shortcuts around safety and other critical processes.

Jaak Peeters, Special Envoy for COVID-19 Vaccine at Johnson & Johnson, said the company is moving at a “very...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

J&J’s Trispecific Antibody For Myeloma Offers Improved Safety, Potency Over Bispecifics

 
• By Alaric DeArment

The drugmaker presented data from its Phase I study of JNJ-79635322 at ASCO and EHA showing a 100% response rate in BCMA- and GPRC5D-naïve patients.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

More from Scrip

Executives On The Move: Fable Therapeutics Gains CMO From AstraZeneca

Recent moves in the industry include changes at the top at 32 Biosciences, plus new CEOs at Idorsia, Courage Therapeutics and Oncolytics Biotech.

China Signals Restarting IPOs For Unprofitable Biotechs

 
• By Dexter Jie Yan

The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.

BIO Notebook: Woodcock Calls For Doing The Right Thing, Dealmaking Remains Constrained

 
• By Mandy Jackson, Joseph Haas, and Sarah Karlin-Smith

Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.